The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual
Open accessAbstract
Answer questions and earn CME/CNE To update the melanoma staging system of the American Joint Committee on Cancer (AJCC) a large database was assembled comprising >46,000 patients from 10 centers worldwide with stages I, II, and III melanoma diagnosed since 1998. Based on analyses of this new database, the existing seventh edition AJCC stage IV database, and contemporary clinical trial data, the AJCC Melanoma Expert Panel introduced several important changes to the Tumor, Nodes, Metastasis (TNM) classification and stage grouping criteria. Key changes in the eighth edition AJCC Cancer Staging Manual include: 1) tumor thickness measurements to be recorded to the nearest 0.1 mm, not 0.01 mm; 2) definitions of T1a and T1b are revised (T1a, <0.8 mm without ulceration; T1b, 0.8‐1.0 mm with or without ulceration or <0.8 mm with ulceration), with mitotic rate no longer a T category criterion; 3) pathological (but not clinical) stage IA is revised to include T1b N0 M0 (formerly pathologic stage IB); 4) the N category descriptors “microscopic” and “macroscopic” for regional node metastasis are redefined as “clinically occult” and “clinically apparent”; 5) prognostic stage III groupings are based on N category criteria and T category criteria (ie, primary tumor thickness and ulceration) and increased from 3 to 4 subgroups (stages IIIA‐IIID); 6) definitions of N subcategories are revised, with the presence of microsatellites, satellites, or in‐transit metastases now categorized as N1c, N2c, or N3c based on the number of tumor‐involved regional lymph nodes, if any; 7) descriptors are added to each M1 subcategory designation for lactate dehydrogenase (LDH) level (LDH elevation no longer upstages to M1c); and 8) a new M1d designation is added for central nervous system metastases. This evidence‐based revision of the AJCC melanoma staging system will guide patient treatment, provide better prognostic estimates, and refine stratification of patients entering clinical trials. CA Cancer J Clin 2017;67:472‐492. © 2017 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
(2017) · Springer eBooks · doi:10.1007/978-3-319-40618-3 · Cited by 17,242
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Self-citationImproved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Self-citationPembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Self-citationNivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
Self-citationFinal Version of 2009 AJCC Melanoma Staging and Classification
Balch, C. M., Gershenwald, J. E., Soong, S.-J., Thompson, J. F., Atkins, M. B., Byrd, D. R., Buzaid, A. C., Cochran, A. J., Coit, D. G., Ding, S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.4799 · Cited by 4,602
Self-citationTechnical Details of Intraoperative Lymphatic Mapping for Early Stage Melanoma
Morton, D. L. (1992) · Archives of Surgery · doi:10.1001/archsurg.1992.01420040034005 · Cited by 4,371
Cited by
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
Long, G. V., Hauschild, A., Santinami, M., Atkinson, V., Mandalà, M., Chiarion-Sileni, V., Larkin, J., Nyakas, M., Dutriaux, C., Haydon, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708539 · Cited by 1,490
Self-citationSchadendorf, D., van Akkooi, A. C. J., Berking, C., Griewank, K. G., Gutzmer, R., Hauschild, A., Stang, A., Roesch, A., & Ugurel, S. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31559-9 · Cited by 1,488
Neoadjuvant checkpoint blockade for cancer immunotherapy
Topalian, S. L., Taube, J. M., & Pardoll, D. M. (2020) · Science · doi:10.1126/science.aax0182 · Cited by 1,001
Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma
Amaria, R. N., Reddy, S. M., Tawbi, H. A., Davies, M. A., Ross, M. I., Glitza, I. C., Cormier, J. N., Lewis, C., Hwu, W.-J., Hanna, E., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0197-1 · Cited by 835
Self-citationLong, G. V., Swetter, S. M., Menzies, A. M., Gershenwald, J. E., & Scolyer, R. A. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00821-8 · Cited by 746
Self-citationGuidelines of care for the management of primary cutaneous melanoma
Swetter, S. M., Tsao, H., Bichakjian, C. K., Curiel-Lewandrowski, C., Elder, D. E., Gershenwald, J. E., Guild, V., Grant-Kels, J. M., Halpern, A. C., Johnson, T. M., et al. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.08.055 · Cited by 727
Self-citationCutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Michielin, O., van Akkooi, A. C. J., Ascierto, P. A., Dummer, R., & Keilholz, U. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz411 · Cited by 617
Keung, E. Z., & Gershenwald, J. E. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1489246 · Cited by 593
Self-citationRozeman, E. A., Menzies, A. M., van Akkooi, A. C. J., Adhikari, C., Bierman, C., van de Wiel, B. A., Scolyer, R. A., Krijgsman, O., Sikorska, K., Eriksson, H., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30151-2 · Cited by 537
Self-citationElder, D. E., Bastian, B. C., Cree, I. A., Massi, D., & Scolyer, R. A. (2020) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2019-0561-ra · Cited by 502
Self-citationLuke, J. J., Rutkowski, P., Queirolo, P., Del Vecchio, M., Mackiewicz, J., Chiarion-Sileni, V., de la Cruz Merino, L., Khattak, M. A., Schadendorf, D., Long, G. V., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00562-1 · Cited by 499
Self-citationMelanoma Staging: American Joint Committee on Cancer (AJCC) 8th Edition and Beyond
Gershenwald, J. E., & Scolyer, R. A. (2018) · Annals of Surgical Oncology · doi:10.1245/s10434-018-6513-7 · Cited by 452
Self-citationBrain malignancies: Glioblastoma and brain metastases
Lah, T. T., Novak, M., & Breznik, B. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.10.010 · Cited by 438
Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
Coit, D. G., Thompson, J. A., Albertini, M. R., Barker, C., Carson, W. E., Contreras, C., Daniels, G. A., DiMaio, D., Fields, R. C., Fleming, M. D., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.0018 · Cited by 436
Self-citationFive-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma
Dummer, R., Hauschild, A., Santinami, M., Atkinson, V., Mandalà, M., Kirkwood, J. M., Chiarion Sileni, V., Larkin, J., Nyakas, M., Dutriaux, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2005493 · Cited by 408
Self-citationEggermont, A. M. M., Blank, C. U., Mandalà, M., Long, G. V., Atkinson, V. G., Dalle, S., Haydon, A. M., Meshcheryakov, A., Khattak, A., Carlino, M. S., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00065-6 · Cited by 387
Self-citationRecent Advances in the Treatment of Melanoma
Curti, B. D., & Faries, M. B. (2021) · New England Journal of Medicine · doi:10.1056/nejmra2034861 · Cited by 386
Self-citationNeoadjuvant relatlimab and nivolumab in resectable melanoma
Amaria, R. N., Postow, M., Burton, E. M., Tetzlaff, M. T., Ross, M. I., Torres-Cabala, C., Glitza, I. C., Duan, F., Milton, D. R., Busam, K., et al. (2022) · Nature · doi:10.1038/s41586-022-05368-8 · Cited by 345
Self-citationClinical Development of BRAF plus MEK Inhibitor Combinations
Subbiah, V., Baik, C., & Kirkwood, J. M. (2020) · Trends in Cancer · doi:10.1016/j.trecan.2020.05.009 · Cited by 344
Self-citationDeep Adversarial Training for Multi-Organ Nuclei Segmentation in Histopathology Images
Mahmood, F., Borders, D., Chen, R. J., Mckay, G. N., Salimian, K. J., Baras, A., & Durr, N. J. (2020) · IEEE Transactions on Medical Imaging · doi:10.1109/tmi.2019.2927182 · Cited by 340
Swetter, S. M., Thompson, J. A., Albertini, M. R., Barker, C. A., Baumgartner, J., Boland, G., Chmielowski, B., DiMaio, D., Durham, A., Fields, R. C., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0018 · Cited by 340
Self-citationTreatment of Advanced Melanoma in 2020 and Beyond
Jenkins, R. W., & Fisher, D. E. (2021) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2020.03.943 · Cited by 339
European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: Update 2022
Garbe, C., Amaral, T., Peris, K., Hauschild, A., Arenberger, P., Basset-Seguin, N., Bastholt, L., Bataille, V., del Marmol, V., Dréno, B., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.03.008 · Cited by 329
Talimogene Laherparepvec (T-VEC): An Intralesional Cancer Immunotherapy for Advanced Melanoma
Ferrucci, P. F., Pala, L., Conforti, F., & Cocorocchio, E. (2021) · Cancers · doi:10.3390/cancers13061383 · Cited by 317
T cell–induced CSF1 promotes melanoma resistance to PD1 blockade
Neubert, N. J., Schmittnaegel, M., Bordry, N., Nassiri, S., Wald, N., Martignier, C., Tillé, L., Homicsko, K., Damsky, W., Maby-El Hajjami, H., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aan3311 · Cited by 308
Eggermont, A. M. M., Blank, C. U., Mandala, M., Long, G. V., Atkinson, V. G., Dalle, S., Haydon, A. M., Meshcheryakov, A., Khattak, A., Carlino, M. S., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.02110 · Cited by 288
Self-citationPathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma
Tetzlaff, M. T., Messina, J. L., Stein, J. E., Xu, X., Amaria, R. N., Blank, C. U., van de Wiel, B. A., Ferguson, P. M., Rawson, R. V., Ross, M. I., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy226 · Cited by 284
Self-citationEuropean consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022
Garbe, C., Amaral, T., Peris, K., Hauschild, A., Arenberger, P., Basset-Seguin, N., Bastholt, L., Bataille, V., del Marmol, V., Dréno, B., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.04.018 · Cited by 283
Systemic Therapy for Melanoma: ASCO Guideline
Seth, R., Messersmith, H., Kaur, V., Kirkwood, J. M., Kudchadkar, R., McQuade, J. L., Provenzano, A., Swami, U., Weber, J., Alluri, K. C., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00198 · Cited by 265
Self-citationTeledermatology for diagnosing skin cancer in adults.
Chuchu, N., Dinnes, J., Takwoingi, Y., Matin, R. N., Bayliss, S. E., Davenport, C., Moreau, J. F., Bassett, O., Godfrey, K., O'Sullivan, C., et al. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013193 · Cited by 175
Al-Adra, D. P., Hammel, L., Roberts, J., Woodle, E. S., Levine, D., Mandelbrot, D., Verna, E., Locke, J., D’Cunha, J., Farr, M., et al. (2021) · American Journal of Transplantation · doi:10.1111/ajt.16324 · Cited by 87
Cerminara, S. E., Cheng, P., Kostner, L., Huber, S., Kunz, M., Maul, J.-T., Böhm, J. S., Dettwiler, C. F., Geser, A., Jakopović, C., et al. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.112954 · Cited by 62
Felmingham, C. M., Adler, N. R., Ge, Z., Morton, R. L., Janda, M., & Mar, V. J. (2021) · American Journal of Clinical Dermatology · doi:10.1007/s40257-020-00574-4 · Cited by 57
Hurkmans, D. P., Jensen, C., Koolen, S. L. W., Aerts, J., Karsdal, M. A., Mathijssen, R. H. J., & Willumsen, N. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001193 · Cited by 49
Clinical protein science in translational medicine targeting malignant melanoma
Gil, J., Betancourt, L. H., Pla, I., Sanchez, A., Appelqvist, R., Miliotis, T., Kuras, M., Oskolas, H., Kim, Y., Horvath, Z., et al. (2019) · Cell Biology and Toxicology · doi:10.1007/s10565-019-09468-6 · Cited by 45
Betancourt, L. H., Szasz, A. M., Kuras, M., Rodriguez Murillo, J., Sugihara, Y., Pla, I., Horvath, Z., Pawłowski, K., Rezeli, M., Miharada, K., et al. (2019) · Cancers · doi:10.3390/cancers11121981 · Cited by 24
Garrido, A. Q., Wainstein, A. J. A., Brandão, M. P. A., de Vasconcellos Santos, F. A., Bittencourt, F. V., Ledsham, C., & Drummond-Lage, A. P. (2020) · Journal of Cancer Education · doi:10.1007/s13187-020-01735-z · Cited by 15
Li, X., Yu, X., Tian, D., Liu, Y., & Li, D. (2023) · Medical Physics · doi:10.1002/mp.16748 · Cited by 6
Impact of particulate matter exposure on melanoma risk: A multicentre case–control study
Bellinato, F., Adami, G., Reatini, M. A., Cattani, G., Cannizzaro, M. V., Del Regno, L., Peris, K., Gisondi, P., & Girolomoni, G. (2025) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.20539 · Cited by 3
Digital quantification of Ki67 and PRAME in challenging melanocytic lesions—A novel diagnostic tool
Brogård, M. B., Steiniche, T., Lade-Keller, J., Wandler, A., Christensen, K. B., Georgsen, J. B., & Nielsen, P. S. (2025) · Pathology - Research and Practice · doi:10.1016/j.prp.2025.155953 · Cited by 1
Metadata
- Authors
- Gershenwald, J. E., Scolyer, R. A., Hess, K. R., Sondak, V. K., Long, G. V., Ross, M. I., Lazar, A. J., Faries, M. B., Kirkwood, J. M., McArthur, G. A., Haydu, L. E., Eggermont, A. M. M., Flaherty, K. T., Balch, C. M., Thompson, J. F., & for members of the American Joint Committee on Cancer Melanoma Expert Panel and the International Melanoma Database and Discovery Platform
- Venue
- CA: A Cancer Journal for Clinicians
- Publisher
- Wiley
- Published
- 2017-10-13
- Volume
- 67
- Issue
- 6
- Pages
- 472-492
- ISSN
- 0007-9235 (ISSN-L)
- 1542-4863
- OpenAlex
- W2762347490
- Cited by
- 2,283
- References
- 53
- FWCI
- 87.89
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.